Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Objective: To highlight the benefit of thrombophilia screening and antithrombotic therapy in consecutive unexplained pregnancy losses. Case Report: The authors presented a detailed description and follow-up of a 37-year-old patient with a history of 11 miscarriages between the sixth and eighth weeks of gestation. In her eighth pregnancy, she was considered as unexplained recurrent pregnancy loss (RPL) and received lymphocyte immunization. However, the patient still experienced subsequent four spontaneous abortions at the similar gestational age. In the outpatient departments, she was diagnosed as thrombophilia and then she received low molecular weight heparin (LMWH) subcutaneous daily injection after ovulation and 50 mg aspirin daily orally started two months before pregnancy until the 32nd week of gestation. At 36+2 gestational weeks, a male infant was born in good condition with weight of 3,410 grams. Conclusion: Early start of LMWH and aspirin decreases the incidence of miscarriage in women with unexplained RPL.